1-20 of 32 Search Results for

*

Phase I clinical trials
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V. Long, Miguel F. Sanmamed, Anna Spreafico, Elizabeth Buchbinder, Mario Sznol, Hans Prenen, Alexander Fedenko, Mohammed Milhem, Ana Maria Arance Fernandez, Jean-Jacques Grob, Lev Demidov, Caroline Robert, Christin Habigt, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Nicole Martin, Christophe Boetsch, Jehad Charo, Volker Teichgraeber, Anton Kraxner, Nino Keshelava, Oliver Bechter
Journal: Cancer Research Communications
Cancer Research Communications (2025)
https://doi.org/10.1158/2767-9764.CRC-24-0601
Published: 03 February 2025
View article titled, Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma
Open the PDF for Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

Shivaani Kummar, Albiruni Abdul Razak, Scott Laurie, Dylan M. Glatt, Sariah Kell, Anh N. Diep, Maike Schmidt, Clifford Hom, Chris German, Suyash S. Shringarpure, Sophia R. Majeed, Drew Rasco
Journal: Cancer Research Communications
Cancer Research Communications (2025) 5 (1): 94–105.
https://doi.org/10.1158/2767-9764.CRC-24-0568
Published: 15 January 2025
View article titled, First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies
Open the PDF for First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma

Todd Shearer, Melissa Comstock, Rex L. Williams, Jr, Mark C. Johnson, Ewa Cendrowicz, Cathrine Leonowens, Margaret Smith, Todd M. Baughman, Caroline J. Breitbach, Shinta Cheng, Damian J. Green
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (12): 3114–3123.
https://doi.org/10.1158/2767-9764.CRC-24-0075
Published: 11 December 2024
View article titled, Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma
Open the PDF for Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Benjamin Garmezy, Mitesh J. Borad, Rastilav Bahleda, Cesar A. Perez, Li-Tzong Chen, Shumei Kato, Do-Youn Oh, Paul Severson, Betty Y. Tam, Cheng S. Quah, James J. Harding
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1165–1173.
https://doi.org/10.1158/2767-9764.CRC-24-0137
Published: 30 April 2024
View article titled, A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Open the PDF for A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1100–1110.
https://doi.org/10.1158/2767-9764.CRC-24-0082
Published: 18 April 2024
View article titled, First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Laura F. Mendez Luque, Julio Avelar-Barragan, Hellen Nguyen, Jenny Nguyen, Eli M. Soyfer, Jiarui Liu, Jane H. Chen, Nitya Mehrotra, Xin Huang, Heidi E. Kosiorek, Amylou Dueck, Alexander Himstead, Elena Heide, Melinda Lem, Kenza El Alaoui, Eduard Mas, Robyn M. Scherber, Ruben A. Mesa, Katrine L. Whiteson, Andrew Odegaard, Angela G. Fleischman
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (3): 660–670.
https://doi.org/10.1158/2767-9764.CRC-23-0380
Published: 05 March 2024
View article titled, The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence
Open the PDF for The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence in another window
Includes: Supplementary data
Journal Articles

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Vivek Subbiah, Niamh Coleman, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Jordi Rodon, Shubham Pant, Ecaterina E. Ileana Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (2): 378–387.
https://doi.org/10.1158/2767-9764.CRC-22-0260
Published: 12 February 2024
View article titled, Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <em>mTOR/AKT/PI3K</em> Pathway Alterations and Advanced Solid Malignancies
Open the PDF for Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <em>mTOR/AKT/PI3K</em> Pathway Alterations and Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study

Pamela Munster, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F. Stephen Hodi, Niharika B. Mettu, Mark Jones, Jill Bowman, Michael Smith, Mani Lakshminarayanan, Steven O'Day
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (12): 2572–2584.
https://doi.org/10.1158/2767-9764.CRC-22-0461
Published: 19 December 2023
View article titled, Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer

Vikram Malhi, Priya Agarwal, Mary R. Gates, Lichuan Liu, Jianshuang Wang, Tom De Bruyn, Scott Lam, Jennifer Eng-Wong, Pablo Perez-Moreno, Ya-Chi Chen, Jiajie Yu
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (12): 2551–2559.
https://doi.org/10.1158/2767-9764.CRC-23-0324
Published: 15 December 2023
View article titled, Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Open the PDF for Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib

Paul B. Chapman, Mark Klang, Michael A. Postow, Alexander Noor Shoushtari, Ryan J. Sullivan, Jedd D. Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K. Callahan, Bin Zheng, Jonathan Zippin
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (12): 2447–2454.
https://doi.org/10.1158/2767-9764.CRC-23-0296
Published: 04 December 2023
View article titled, Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
Open the PDF for Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Glenn J. Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon, Myung-Ju Ahn, Hye Ryun Kim, Andreas Schneeweiss, Josep-Maria Ribera, Daniel DeAngelo, Jose Manuel Perez Garcia, Javier Cortes, Oliver Schönborn-Kellenberger, Dirk Weber, Pavel Pisa, Michael Bauer, Laura Beni, Maria Bobadilla, Raj Lehal, Michele Vigolo, Florian D. Vogl, Elena Garralda
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1853–1861.
https://doi.org/10.1158/2767-9764.CRC-23-0333
Published: 14 September 2023
View article titled, A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Open the PDF for A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors in another window
Includes: Supplementary data
Journal Articles

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1662–1671.
https://doi.org/10.1158/2767-9764.CRC-23-0284
Published: 28 August 2023
View article titled, Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Open the PDF for Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens in another window
Includes: Supplementary data
Journal Articles

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

H. Catherine Wilbur, Jennifer N. Durham, Su Jin Lim, Katrina Purtell, Katherine M. Bever, Daniel A. Laheru, Ana De Jesus-Acosta, Nilofer S. Azad, Bradley Wilt, Luis A. Diaz, Dung T. Le, Hao Wang
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1672–1677.
https://doi.org/10.1158/2767-9764.CRC-23-0230
Published: 28 August 2023
View article titled, Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
Open the PDF for Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors

Michael A. Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1638–1647.
https://doi.org/10.1158/2767-9764.CRC-23-0048
Published: 24 August 2023
View article titled, A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors in another window
Journal Articles

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

Vina P. Nguyen, Katie M. Campbell, Theodore S. Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga-Carretero, Maggie L. DiNome, Helena R. Chang, Denise K. Oseguera, Antoni Ribas, John A. Glaspy
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1628–1637.
https://doi.org/10.1158/2767-9764.CRC-23-0145
Published: 23 August 2023
View article titled, A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Open the PDF for A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme

Jason D. Lickliter, Jeremy Ruben, Ganessan Kichenadasse, Ross Jennens, Cecelia Gzell, Ralph P. Mason, Heling Zhou, Jennifer Becker, Evan Unger, Baldassarre Stea
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1607–1614.
https://doi.org/10.1158/2767-9764.CRC-22-0433
Published: 21 August 2023
View article titled, Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme
Open the PDF for Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme in another window
Journal Articles

Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib

Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, Shunsuke Kondo, Kan Yonemori, Kohei Shitara, Satoshi Shiono, Daiko Matsuoka, Keisuke Yasuda, Yohei Otake, Takuya Suzuki, Takao Takase, Shuya Takashima, Kohei Yamaguchi, Taro Semba, Noboru Yamamoto
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1189–1199.
https://doi.org/10.1158/2767-9764.CRC-22-0401
Published: 10 July 2023
View article titled, Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Open the PDF for Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib in another window
Includes: Supplementary data
Journal Articles

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1113–1117.
https://doi.org/10.1158/2767-9764.CRC-22-0485
Published: 26 June 2023
View article titled, NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
Open the PDF for NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

Elizabeth R. Kessler, Eryn Callihan, Junxiao Hu, Corbin Eule, Geetika Srivastava, Douglas J. Kemme, Praveena Iruku, Vishal Rana, James Moore, Steven R. Schuster, Mali Amirault, Thomas W. Flaig, Elaine T. Lam
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1004–1012.
https://doi.org/10.1158/2767-9764.CRC-23-0060
Published: 08 June 2023
View article titled, A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
Open the PDF for A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer

Jing Wang, Xiaobo Cheng, Yanling Jin, Bili Xia, Ran Qin, Wei Zhang, Huiliang Hu, Xiaoting Mao, Liting Zhou, Jia Yan, Xiaoyan Zhang, Jianqing Xu
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 991–1003.
https://doi.org/10.1158/2767-9764.CRC-23-0137
Published: 07 June 2023
View article titled, Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1<sup>+</sup>CD8<sup>+</sup> T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Open the PDF for Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1<sup>+</sup>CD8<sup>+</sup> T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer in another window
Includes: Supplementary data